![Jérôme Tiollier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jérôme Tiollier
Fondatore presso Jalon Therapeutics
Posizioni attive di Jérôme Tiollier
Società | Posizione | Inizio | Fine |
---|---|---|---|
Jalon Therapeutics
![]() Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Presidente | - | - |
Fondatore | - | - |
Storia della carriera di Jérôme Tiollier
Precedenti posizioni note di Jérôme Tiollier
Società | Posizione | Inizio | Fine |
---|---|---|---|
INNATE PHARMA | Corporate Officer/Principal | 01/09/2001 | - |
Formazione di Jérôme Tiollier
University of Lyon | Undergraduate Degree |
Statistiche
Distribuzione geografica
Francia | 4 |
Posizioni
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chairman | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
INNATE PHARMA | Health Technology |
Aziende private | 1 |
---|---|
Jalon Therapeutics
![]() Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Health Technology |
- Borsa valori
- Insiders
- Jérôme Tiollier
- Esperienza